Hot Investor Mandate 1: Global Asset Manager Seeks Disruptive Medtech in Robotics, Cardiovascular, Cancer, Diabetes and Orthopedics

14 Apr

A global alternative asset manager based in Shenzhen, China focuses on investments in the healthcare sector, currently focusing on acquisition or investment first and then acquisition. The firm is making new investments in venture stage companies from its 2015 vintage fund of US$50 million. Depending on the stage of the company, the firm can invest from several hundred thousand to tens of millions in companies with valuation under 1 billion RMB. The firm considers companies based in the US, Europe, Israel, and Asia with a focus on China-based businesses. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking to invest in medical devices that are novel and disruptive. The firm considers a broad range of medical devices with a focus on robotics, cardiovascular, cancer, diabetes, orthopedics, and ophthalmology. The firm typically invests in clinical stage projects but would consider devices at all stages.

Currently, the firm is only looking for privately held companies and typically requires board representation post-investment. The firm prefers to exit within 5 years, but can be flexible on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: